Neurocrine Biosciences Inc (NBIX): EPS (Diluted)
$4.67
Year ended 2025-12-31
+44.1%
3-year compound annual growth
+2.3%
5-year compound annual growth
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.67 | +41.9% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $3.29 | +33.2% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $2.47 | +58.3% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $1.56 | +69.6% | 2025-02-10, From 2022-01-01 |
| 2021-12-31 | $0.92 | -77.9% | 2024-02-09, From 2021-01-01 |
| 2020-12-31 | $4.16 | +966.7% | 2023-02-09, From 2020-01-01 |
| 2019-12-31 | $0.39 | +77.3% | 2022-02-11, From 2019-01-01 |
| 2018-12-31 | $0.22 | n/m | 2021-02-05, From 2018-01-01 |
| 2017-12-31 | -$1.62 | n/m | 2020-02-07, From 2017-01-01 |
| 2016-12-31 | -$1.63 | n/m | 2019-02-08, From 2016-01-01 |
| 2015-12-31 | -$1.05 | n/m | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | -$0.81 | n/m | 2017-02-14, From 2014-01-01 |
| 2013-12-31 | -$0.69 | n/m | 2016-02-11, From 2013-01-01 |
| 2012-12-31 | $0.08 | -88.1% | 2015-02-09, From 2012-01-01 |
| 2011-12-31 | $0.67 | n/m | 2014-02-11, From 2011-01-01 |
| 2010-12-31 | -$0.15 | n/m | 2013-02-08, From 2010-01-01 |
| 2009-12-31 | -$1.30 | n/a | 2012-02-09, From 2009-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.67 | +41.9% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.78 | +58.0% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $1.94 | +424.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$7.26 | n/m |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.56 | -25.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.16 | +152.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $2.58 | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.21 | n/m |
| Biogen Inc. (BIIB) | 2025-12-31 | $8.79 | -21.4% |
Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗